Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

Using the TipRanks Stock Screener Tool, we identified three companies with high price-to-earnings (P/E) ratios, Strong Buy consensus ratings, and m...

Overvalued? Analysts Say These 3 High P/E Stocks Could Jump 50%+

BTIG analyst Marie Thibault maintained a Buy rating on Insulet on June 15 and set a price target of $235.00. The company’s shares closed yesterday ...

BTIG Remains a Buy on Insulet (PODD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY), Insulet (PODD) and Novartis ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

Raymond James analyst Jayson Bedford maintained a Buy rating on Insulet today and set a price target of $216.00. According to TipRanks, Bedford is ...

Raymond James Sticks to Their Buy Rating for Insulet (PODD)

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Insulet, with a price target of $255.00. Biegelsen covers t...

Wells Fargo Reaffirms Their Buy Rating on Insulet (PODD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Insulet (PODD) with bullis...

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Insulet (PODD)

Insulet ( ($PODD) ) just unveiled an update. On May 26, 2026, Insulet announced a voluntary medical device correction for specific lots of Omnipod ...

Insulet Issues Voluntary Correction for Defective Omnipod Pods

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), is up 0.72% in pre-market trading on Tuesday as investors closely watched de...

Why Is Vanguard S&P 500 ETF (VOO) Rising Today, 5/26/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), closed higher by 0.40% on Friday. Notably, the U.S. stock market is closed t...

Vanguard S&P 500 ETF (VOO) Latest Update

Analysts are intrested in these 5 stocks: ( ($SM) ), ( ($CASY) ), ( ($GILD) ), ( ($D) ) and ( ($PODD) ). Here is a breakdown of their recent


SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), is up 0.63% in early trading on Friday as investors closely watched updates ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PODD	$145.76	+1.56%	2.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PODD	$145.76	+1.6%	2.86M
3
4
5
6

PODD

PODD

Recent News for PODD

Get Insulet Corporation Data in Excel

Get Insulet Corporation Data in Excel